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Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex
Aims: Indices of brain volume [grey matter, white matter
(WM), lesions] are being used as outcomes in clinical tri-
als of patients with multiple sclerosis (MS). We investi-
gated the relationship between cortical volume, the
number of neocortical neurons estimated using stereol-
ogy and demyelination. Methods: Nine MS and seven
control hemispheres were dissected into coronal slices.
On sections stained for Giemsa, the cortex was outlined
and optical disectors applied using systematic uniform
random sampling. Neurons were counted using an oil
immersion objective (9 60) following stereological prin-
ciples. Grey and WM demyelination was outlined on
myelin basic protein immunostained sections, and
expressed as percentages of cortex and WM respectively.
Results: In MS, the mean number of neurons was
14.9  1.9 billion vs. 24.4  2.4 billion in controls
(P < 0.011), a 39% difference. The density of neurons
was smaller by 28% (P < 0.001) and cortical volume by
26% (P = 0.1). Strong association was detected between
number of neurons and cortical volume (P < 0.0001).
Demyelination affected 40  13% of the MS neocortex
and 9  12% of the WM, however, neither correlated
with neuronal loss. Only weak association was detected
between number of neurons and WM volume. Conclu-
sion: Neocortical neuronal loss in MS is massive and
strongly predicted by cortical volume. Cortical volume
decline detected in vivo may be similarly indicative of
neuronal loss. Lack of association between neuronal den-
sity and demyelination suggests these features are par-
tially independent, at least in chronic MS.
Keywords: cortical pathology, neuronal loss, progressive multiple sclerosis
Introduction
Multiple sclerosis (MS) is a chronic inflammatory and
degenerative disease of the central nervous system
(CNS) usually becoming symptomatic in early adulthood
[1,2]. The most obvious pathological findings in the MS
brain consist of focal white matter (WM) demyelination
with microscopic analysis further revealing perivascular
and parenchymal inflammation, a variable degree of
axonal loss, remyelination and gliosis [3].
Although involvement of the grey matter (GM) in
MS pathology has been described for well over one cen-
tury [4–9], the past two decades have seen an
increased interest in measuring the extent, and identi-
fying the cellular basis, of cortical pathology in people
with MS (pwMS), notably demyelination and neuronal
loss [10–13].
Magnetic resonance imaging (MRI) studies assessing
various indices of cortical damage suggest that clinical
measures of disability may be more closely related to
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GM than WM pathology, particularly after onset of pro-
gression [14–17].
However, the histological correlate(s) of volume
changes across the whole neocortex have not been sys-
tematically assessed. Given that indices of brain volume
have emerged as key outcome measures in natural his-
tory studies and treatment trials of new disease modify-
ing agents, establishing the quantitative cellular basis
of volumetric changes in the brain is of significant
importance [18].
Although previous observations have established the
presence of neuronal loss in the MS neocortex, there is
significant variation in the reported magnitude, rang-
ing between 18% [19] and up to 65% in individual
cortical layers [13]. The variation in the degree of neu-
ronal loss reported in these studies may have arisen
from variability in the available post mortem material,
differences in sampling strategy and the application of
a two-dimensional approach to histological quantifica-
tion [20].
Moreover, the impact of neocortical demyelination
on neuronal loss and cortical volume across the whole
brain has remained unclear. Peterson and co-workers
described an increase of neuronal apoptosis in demyeli-
nated neocortex [21]; however, the reported association
between neuronal loss and demyelination was either
mild (10% loss in demyelinated vs. nondemyelinated
cortical areas) or nonsignificant [13,19,22,23]. Given
the difficulties detecting cortical lesions using MRI
in vivo as well as post mortem, at least when using stan-
dard clinical MR systems [24–26], careful quantitative
autopsy studies to further explore the association
between myelination status, neuronal loss and cortical
volume change are warranted [27].
In this study, we quantified the number of neurons
across the whole neocortex of pwMS using unbiased
stereological methods to estimate the overall extent of
neuronal loss. We then investigated the association
between the number of neocortical neurons and (i) the
degree of cortical and WM demyelination and (ii) corti-
cal and WM volume.
Materials and methods
Brain specimens and clinical data
This study was performed on formalin-fixed post mortem
brain hemispheres from nine pwMS, seven secondary
progressive (SP) MS and two primary progressive (PP)
MS, of which six were female and three male. Control
brain tissues from seven healthy donors (three females
and four males) with no history or pathological evi-
dence of neurological disease were used as a reference.
MS cases were selected to provide a wide age range at
death (Table 1).
The diagnosis of MS, as well as the absence of any
other confounding pathology in our cohort of cases,
was confirmed based on the patient history (reviewed
by Klaus Schmierer and Daniele Carassiti) and on a
detailed neuropathological inspection (conducted by
Francesco Scaravilli, Daniele Carassiti, Natalia Petrova
and Klaus Schmierer): at least five tissue blocks, dis-
sected without compromising the integrity of the neo-
cortex for subsequent stereological analysis, were
sampled from the following regions: hippocampus and
entorhinal cortex, F2 frontal cortex, the pericallosal
gyrus, corpus callosum and the periventicular WM,
occipital and temporal cortices. We then assessed with
light microscopy the presence of inflammatory infil-
trates and described the demyelinated lesions according
to Kuhlmann and colleagues [28]. All dissected tissue
blocks were stained for haematoxilin and eosin, Luxol
fast blue and immunostained for CD68 to reveal micro-
glial cells. In 7 out of 16 cases with an older age at
death (two controls and five MS, aged 92 and 81 and
55–73 years respectively), immunohistochemistry
(IHC) was carried out to assess the presence of Lewy
bodies, b-amyloid and neurofibrillary (NFT) tangles.
The antibodies used and corresponding immunohisto-
chemical methods are summarized in Table S1.
Tissue dissection
Following the separation of the cerebellum and brain-
stem from the forebrain at the level of the midbrain, the
hemispheres were separated by an anteroposterior cut
through the corpus callosum and weighed. Lobar topog-
raphy was marked on the cortical surface using tissue
dye (Sigma-Aldrich, St. Louis, Missouri, USA) so that the
three frontal gyri, the motor, the parietal/temporal and
the occipital cortices, were identified. Brain hemispheres
were then dissected into parallel coronal slices with a
thickness of 11 mm using a custom-made Perspex tissue
holder including cutting panel (Schmierer GmbH, Gross-
Gerau, Germany). The total surface area of each forma-
lin-fixed coronal slice was measured before and after
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tissue processing. The tissue shrinkage factor (SF) was
then calculated and expressed as a percentage loss of the
formalin-fixed surface area prior to tissue processing.
Tissue processing, embedding and staining
Coronal slices were processed for paraffin-embedding
using a Thermo Scientific Excelsior ES tissue processing
machine (Kalamazoo, Michigan, USA). Due to the thick-
ness of the brain slices the processing protocol was opti-
mized to a duration of 80 h. All samples were first
immersed in industrial methylated spirit at 30°C for
39 h (divided into six steps of 1, 4, 6, 8, 10 and 10 h),
then dehydrated in toluene at 30°C for 14 h (three steps
of 4, 5 and 5 h), followed by a final incubation in liquid
paraffin at 62°C for 27 h (three steps of 6, 9 and 12 h).
For each incubation step the solution was automatically
changed and stirred. During embedding each slice was
kept in the same orientation as it had been during dissec-
tion. Care was taken to embed the cutting side parallel to
the surface of the paraffin block. Whole hemispheric sec-
tions were then cut using a Reichert-Jung Tetrander.
The first 40-lm-thick section including the entire hemi-
spheric surface of the coronal slice was mounted on pre-
coated glass slides and instantly dried at 40°C for 24 h,
then preheated at 60°C for at least 2 h before dewaxing
in xylene, rehydrating in industrial methylated spirit and
staining with modified Giemsa stain solution (50 ml
Giemsa by Merck, Kenilworth, NJ, USA cat. no.
1.09204, with 200 ml potassium–hydrogen–phosphate
at pH 4.5 for 1 l of final solution, filtered before use) for
about 3 h. Finally the sections were differentiated with
0.5% acetic acid and dehydrated before mounting them
in DPX mounting medium (VWR, Radnor, PA, USA).
Table 1. Clinical information on all post mortem MS and control specimens included in this study
MS case/subtype
Cause of death Sex Age at onset Age at wheelchair Age at death PMD (h) Fixation time (m) Hemisphere weight (g)
MS 232/SP
Bronchopneumonia
M 40 72 92 23 129 472
MS 453/SP
Pneumonia
M 28 48 68 33 58 514
MS 455/PP
Chest infection
F 50 55 69 32 59 463
MS 463/SP
Bronchopneumonia
F 17 27 47 39 55 412
MS 464/PP
Bronchopneumonia
F 57 n.d. 61 41 43 535
MS 468/SP
Unknown
F 24 n.d. 55 48 45 555
MS 471/SP
Pulmonary fibrosis,
asbestos exposure
F 60 86 86 47 53 456
MS475/PP
Pneumonia (bilateral)
M 58 67 73 12 52 448
MS 550/SP
Urinary infection
F 42 59 64 n.d. 36 442
Case Sex Age at death PMD Fixation time (m) Hemisphere weight (g) Cause of death
C50 F 53 12 336 573 Myocardial infarction
C55 F 92 60 336 498 Cardiac arrest
C56 M 82 50 58 490 Aspiration pneumonia
C58 M 89 15 50 485 General deterioration
C60 M 78 10 47 525 Pancreatic cancer
C61 M 81 27 47 669 Ischaemic heart disease
C188 F 47 24 324 625 Metastatic ovary cancer
PMD, post mortem delay; h, hours; m, months; g, grams; M, males; F, females; MS, multiple sclerosis; SP, secondary progressive;
PP, primary progressive.
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Stereological analysis
Stereological analysis (DC) was performed using a stere-
ology workstation consisting of a modified light micro-
scope (Nikon Eclipse 80i, Minato, Tokyo, Japan)
equipped with a PlanUW objective 29 [numerical aper-
ture (NA) = 0.06], a 609 PlanApo oil-immersion
objective (NA = 1.4) (Nikon, Tokyo, Japan), an inte-
grated motorized stage for automated sampling (MBF
Bioscience, Williston, VT, USA), a CCD colour video
camera (CX9000; MBF Bioscience) and stereology soft-
ware (StereoInvestigator; MicroBrightField, Williston,
VT, USA).
Forty-lm-thick Giemsa-stained coronal hemispheric
sections were inserted on a custom-made section
holder, and then area of interest (AOI), in this case the
whole neocortical ribbon, was manually outlined and
measured using a 29 objective. The neocortical vol-
ume was calculated for each slice using the following
equation:
Vslice ¼ AOI T; (1)
where T was the distance between sections [29]. The
total number of neurons per slice was equal to the vol-
ume of the reference space (neocortex) per slice multi-
plied by the numerical density of neurons = NV. The
NV was equal to the total number of neurons counted
in the slice (∑Q-) divided by the total volume of all
disectors in which those neurons were sampled
= ∑Q-/∑disectors volume. The volume of one disector
was equal to the area of the frame of the disector,
50 9 50 lm, multiplied by the height of the disector
(20 lm), that is, 50 000 lm3. StereoInvestigator Soft-
ware placed disectors over the AOI using a systematic
uniform random sampling protocol and an x–y step
length of x = 3455 lm and y = 4655 lm. Step
lengths were defined such that even the smaller AOIs,
for example, in the most anterior slices of the frontal
cortex and the most posterior ones in the occipital cor-
tex, would be covered by at least 10 disectors and were
then kept constant for all samples. The protocol
thereby avoided underestimation of these cortical
regions. The cell counting was performed using the
optical disector method [30–32]. The method is a
slight modification of existing techniques, which have
been considered efficient and reliable in studies of rat
[33] and human neocortex [34]. The optical disector is
a three-dimensional probe generated with the aid of a
microscope with a high numerical aperture and oil
immersion objective, in which it is possible to observe
thin focal planes in relatively thick sections. A count-
ing frame with ‘exclusion’ and ‘inclusion’ lines was
superimposed on the magnified image of the tissue on
a computer screen and the orientation in the z-axis
was measured with a digital microcator with a preci-
sion of 0.5 lm. The purpose of ‘exclusion’ and ‘inclu-
sion’ lines of the counting frame is to exclude edge
effects arising from subsampling [35]. All cells that
come into focus within the frame and not in focus at
the uppermost position were counted as the focal plane
was moved 20 lm through the section. Giemsa-stained
neurons were identified according to the following
morphological criteria: a triangular cellular shape, a
vesicular nucleus, a single large nucleolus free of any
surrounding heterochromatin and a visible cytoplasm
with interspersed ribosomes [36]. The neuronal
nucleus was used as the counting item: on average,
125  54 neuronal nuclei were counted per slice, with
an average number of neurons of 1787  522
counted for each brain (mean  SD). The number of
neurons in each slice was subsequently calculated
according to:
NV  Vref (2)
and the total number of neocortical neurons (TNNN)
determined as the sum total number of neurons in all
slices from one hemisphere multiplied by two (Fig-
ure 1A–C). This result is an unbiased estimate as the
hemispheres were chosen systematically at random
based on the assumption that both brain hemispheres
in one individual contain the same number of neocorti-
cal neurons (in control cases: 4 right vs. 3 left hemi-
spheres; in MS cases: 2 right vs. 7 left; in the whole
cohort: 5 right vs. 11 left).
To explore association between TNNN and WM vol-
ume, the latter was also manually outlined and calcu-
lated as described above for cortical volume.
Quantification of demyelination
The extent of GM and WM demyelination was manu-
ally outlined on 10-lm-thick hemispheric coronal
sections, adjacent to Giemsa-stained sections (Fig-
ure 2A), using myelin basic protein (MBP) IHC (SMI-
94; Covance, Cambridge Bioscience, London UK)
following an established protocol [26] (Figure 2B). The
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quantification of demyelination was performed on a
mean of 6 (range = 4–14) slices/hemisphere selected
using systematic uniform random sampling covering
all cortical regions investigated.
All images were acquired at 9 2 magnification
using the stereology workstation with optimized
settings for light intensity, exposure and white bal-
ance, depending on the objective in use and kept
constant during every acquisition session. Images
were saved as .TIFF files with spatial reference infor-
mation settings for each objective based on calibra-
tion images.
Figure 1. Stereology. Indices acquired for unbiased estimates of the total number of neocortical neurons (TNNN). Each brain hemisphere
was dissected into parallel coronal slices (A). The neocortical area of interest (AOI) was then manually outlined and measured (B). The
AOI was then multiplied by the slice thickness (t), which was adjusted by the shrinkage factor (SF), to obtain the cortical volume
estimate of that slice (Vref). This volume was then multiplied by the density of neurons counted in the disectors placed within that slice
(Nv). TNNN was then obtained as the sum total of neurons in each slice multiplied by 2 (C). Adapted from Artacho-Perula et al. 2004,
Brain Res [37].
Figure 2. Assessment of cortical volume and demyelination. Exemplary adjacent sections of a hemispheric coronal multiple sclerosis
brain slice stained for Giemsa (A) and immunostained for myelin basic protein (B). The blue line indicates the border between white
matter (WM) and neocortex, the red and green lines indicate cortical and WM demyelination respectively. Images acquired with a 9 2
objective. Scale bars = 1 cm.
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Files were then opened using ImageJ Software Devel-
oped by Wayne Rasband (retired from NIH) as public
domain software, and GM demyelination manually out-
lined on the digitized images of MBP immunostained
sections, including all cortical lesion types [21], and
expressed as a percentage of the total cortex on each
slide. The same images were used to manually outline
WM demyelination.
Statistical analysis
Demographics are reported as mean  SD and compared
using Student’s t-test. Differences between pwMS and
controls were examined using linear mixed models with
the measure being compared as the response variable,
and a fixed effect group indicator; fixed effect cortical
region indicators were included in all models, and other
potential confounders (age, gender, SF and disease dura-
tion, for which controls were assigned a zero value in
comparisons with pwMS) were included singly as fixed
effect covariates. These models used the coronal slice as
the unit of analysis, with a random subject intercept to
account for the ownership of slices by subjects. Possible
variations in pwMS vs. control differences by region were
examined by adding a group 9 region interaction term
to the models. Linear mixed models were also used to
investigate associations, in patients only, between corti-
cal pathology measures. Residuals were examined to
check model assumptions, as a result of which number
of neurons, cortical and WM volumes per slice were log
transformed, which generally improved residual normal-
ity and homoscedasticity. Restricted maximum likeli-
hood estimation was used except where there was
evidence of residual heteroscedasticity, when maximum
likelihood was used with robust standard errors. Pear-
son’s test was used only to investigate the association
between the entire cortical volume and the total number
of neurons with a whole brain as a unit of analysis. All
calculations were performed in Stata 13 (Stata
Corporation, College Station, TX, USA) and Prism 6
(GraphPad, San Diego, CA, USA) and significance is
reported at 5%.
Results
Histological sampling and cohort details
A total of 16 cerebral hemispheres were dissected into
229 coronal slices (14 slices/hemisphere, range = 13–
17 slices) and analysed in this study. pwMS did not differ
from controls with respect to age at death (68  14 years,
range = 47–92 years vs. 75  18 years, range = 47–92,
P = 0.44), post mortem delay (34  12 h vs. 29  19 h,
P = 0.5) and fixation time (59  27 months vs.
171  150 months, P = 0.26), the latter was in particu-
lar very long for three female controls, however, these out-
lier data does not affect our analysis and overall
observations. Hemispheres of pwMS were lighter than con-
trols (477  47 g vs. 552  72 g, P = 0.02), a 14% dif-
ference, and SF after processing more pronounced in pwMS
than in controls (28  11% and 25  11%, t-test
P = 0.027).
Microscopic inspection of tissue blocks for pathology
reporting showed only sparse inflammation, either in
WM parenchyma or within perivascular spaces or in
the depth between two banks of a gyrus, where menin-
geal inflammation has been reported to be found more
frequently [11]. Therefore, we did not characterize
meningeal inflammation any further in our cohort. No
active WM lesions were observed.
In order to rule out possible comorbidity, such as
Parkinson’s or Alzheimer’s disease, we investigated sec-
tions using morphological and IHC methods. No evi-
dence of Lewy bodies or a-synuclein-positive
intracytoplasmatic inclusions was found in any of the
brains examined (Figure S1D,G). A b-amyloid deposi-
tion was also absent from the hippocampus of all con-
trols and MS cases (not shown). In one MS case
Figure 3. Neocortical neuronal numbers and their correlation with tissue volumes and demyelination in nine multiple sclerosis brain
hemispheres and seven controls. The total number of cortical neurons in men (dots) and women (squares) with multiple sclerosis (MS)
was 39% lower compared to control brains (A) while the density of neurons was lower by 28% (B). The mean proportion of tissue
demyelinated was fourfold greater in the grey compared to the white matter (C). No statistically significant evidence was detected for an
association between neuronal density and cortical grey matter demyelination (D). However, strong correlation was detected between the
number (n) of cortical neurons and cortical volume in MS (E) and controls (F). This association was also confirmed using Pearson’s
correlation (G). Weak correlation was detected between white matter volume and n cortical neurons (H). In A, B and G values are
presented using ‘whole brain’ as the unit of analysis; C–F, H are presented on a ‘per brain slice’ basis. Error bars and dotted lines
represent 95% confidence intervals.
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2018; 44: 377–390
382 D. Carassiti et al.
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2018; 44: 377–390
Cortical neuronal loss in multiple sclerosis 383
(MS455), diffuse ab-amyloid plaques in the neocortex
were observed; a few such plaques were also seen in
the neocortex of the oldest control case (C55) (Fig-
ure S1E,H). The same control (92-year-old) was also
found to have very sparse NFT-positive neurons in the
dentate gyrus, and also some in the neocortex (Fig-
ure S1F). Similarly, a very low numbers of NFT-positive
neocortical neurons were observed in two MS patients
(MS475 and MS455, Figure S1I).
Loss of neocortical neurons in MS
In pwMS, the TNNN was 14.9  1.9 billion vs.
24.4  2.4 billion in controls (mean  SD) showing
that there were 39% fewer neurons in the neocortex of
pwMS than in controls after adjusting for age, gender,
disease duration and SF [95% CI (13, 58), P = 0.011,
Figure 3A). There was no evidence that this difference
varied significantly across the frontal, motor, parietal/
temporal and occipital cortical regions (P = 0.72). The
number of neurons in each cortical region are listed in
Table 2.
Extent of neocortical ‘atrophy’ in MS
After adjustment for age, gender, disease duration and
SF, we detected trend difference in total cortical volume
with pwMS having a 26% smaller cortical volume than
controls (P = 0.1). There was no evidence of different
volume reductions across the four cortical regions anal-
ysed (P = 0.77).
Lower neuronal density in the MS neocortex
After adjusting for age, gender, disease duration, cortical
region and SF, the mean neuronal density [neurons/
mm3  SEM] in pwMS was 57 468  3636 and
79 787  3869 in controls (mean  SEM, P = 0.0008)
indicating a significant 28% reduction in neuronal den-
sity (Figure 3B). Neuronal density was significantly
smaller in women compared to men, in pwMS
(P < 0.001) and in controls group (P < 0.001). See
Table 3 for the mean neuronal density and the propor-
tional decrease in neuronal density measures in pwMS
and controls, both males and females.
We observed a significant decrease of neuronal den-
sity in each cortical region in pwMS when compared to
controls (see Table 4, all Ps < 0.001).
As expected, we detected a significantly higher neu-
ronal density in the occipital cortex compared to the
other cortical regions in both MS and controls
(P < 0.001). There was no statistical evidence that the
difference in the neuronal density observed between
cortical regions followed a different pattern in pwMS
and controls (P = 0.615).
The extent of demyelination
The degree of demyelination was quantified in 57
hemispheric coronal sections of nine MS cases. The
nonadjusted mean proportion of demyelinated cortex in
Table 2. Total number of neurons in each cortical region of one
brain hemisphere in people with MS and in controls expressed as
mean  SD
Cortical region MS (9 109) Controls (9 109)
Frontal 1.75  0.93 3.08  1.4
Motor 1.39  0.78 3.25  0.91
Parietal/temporal 2.6  1.3 3.4  1.1
Occipital 1.8  0.77 2.5  1.5
MS, multiple sclerosis.
Table 3. Average neuronal densities and relative loss of neocorti-
cal neurons comparing female and male, people with MS and con-
trols
Males Females Difference (%)
MS brain 67 051  5716 54 236  3922 12 815 (19)
Control brain 84 185  4597 73 649  5153 10 536 (12)
Loss (%) 17 134 (20) 19 413 (26)
Mean  SEM (neurons/mm3).
MS, multiple sclerosis.
Table 4. Average neuronal densities and the relative loss of neo-
cortical neurons comparing frontal, motor, parietal/temporal and
occipital cortices of people with MS with controls
Cortical region Patients Controls Difference (%)
Frontal 51 060  4002 73 163  4219 22 103 (30)
Motor cortex 54 145  4213 77 520  4402 23 375 (30)
Parietal/
temporal
52 859  4191 76 450  4431 23 591 (30)
Occipital 73 773  4199 96 863  4440 23 090 (24)
Mean  SEM (neurons/mm3).
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MS was 40  13%. There was no evidence that
demyelination varied by gender (P = 0.99), age
(P = 0.794) or disease duration (P = 0.2). All cortical
regions included in our analysis showed significantly
less demyelination than frontal cortex (motor cortex,
P = 0.004; parietal and temporal cortices, P = 0.017;
occipital cortex P < 0.001) which was the most
severely affected (see Table 5 for the relative demyeli-
nation in each cortical region).
There was no significant gender difference in terms
of proportional cortical demyelination between
males and females (M = 42  11%, F = 39  7%;
P = 0.737).
The mean proportion of demyelination in WM
(9  12%) was fourfold smaller than in the GM
(P < 0.0001, Figure 3C). There was no evidence that
WM demyelination varied by gender (P = 0.43), age
(P = 0.11) or disease duration (P = 0.99).
No association between neuronal loss and
demyelination
After adjusting for age, gender and SF, no significant
association was detected between the percentage of cor-
tical demyelination and the neuronal density, neither
across the entire cortex (P = 0.21, Figure 3D) nor in
specific cortical regions (P = 0.322). No association
was detected either between the number of cortical
neurons and WM lesion volume (P = 0.11).
Association between number of cortical neurons and
tissue volumes
After adjusting for age, gender and SF, a greater corti-
cal volume correlated strongly with a greater number
of cortical neurons (P < 0.001). This correlation, when
tested in each brain slice, was significantly different in
pwMS compared to controls (P < 0.001), with pwMS
showing a shallower regression line (49 787/mm3)
than controls (68 848/mm3), thereby indicating lower
neuronal density in the MS cortex (Figure 3E,F).
In addition, we detected significant correlation between
WM volume and the number of neocortical neurons in
the same slab: for each additional mm3 of WM volume,
we detected a corresponding increase of 0.005% in the
number of neocortical neurons (P = 0.004, Figure 3H).
Further statistical calculations, applying instead the
Pearson’s test on the ‘total cortical volume’ and the
‘total n cortical neurons’ as the unit of analysis,
confirmed a strong association between these two
quantities (Figure 3G, r = 0.86; P < 0.0001).
Discussion
Given various in vivo indices of brain volume are in use
to monitor treatment effect in clinical trials of pwMS, it
is important to accurately establish the histological cor-
relates of brain volume changes [38,39]. In this study,
we focussed on the MS neocortex using an unbiased
histological sampling technique and applied the rules of
stereology in order to accurately quantify in post mor-
tem brain the extent of neuronal loss across the entire
neocortex in pwMS and controls and the correlation
between the number of neurons, cortical volume and
cortical demyelination.
After a mean disease duration of 27 years, pwMS
had 39% lower TNNN compared to controls highlight-
ing the substantial loss of the key CNS cell type – neu-
rons – during a life with MS. Neuronal density was
reduced by just under 30%, and as with neuronal loss,
this decrease was a global finding, that is, there was no
difference in terms of proportional neuronal loss among
the lobes investigated, including the occipital (visual)
cortex which – in line with its specific anatomical orga-
nization of layers – showed a higher density of neurons
compared to the frontal, motor, parietal and temporal
cortices. The detected reduction of TNNN in MS, over
and above the reported 10% due to ageing [34], under-
lines the significance of neuronal loss in the MS neo-
cortex. Negligible signs of additional pathology in a few
of our cases are unlikely to have affected the stereologi-
cal estimates in our study.
While the difference in cortical volume between MS
and controls did not reach statistical significance, the
number of neocortical neurons was robustly associated
Table 5. Average proportion of demyelinated grey matter
(mean  SEM) affecting the four cortical regions analysed show-
ing that lesion load is significantly affecting the frontal cortex
more than motor, parietal/temporal and occipital cortices
Cortical region Demyelinated cortex %  SEM
Frontal 46  6
Motor cortex 38  6
Parietal/temporal 39  7
Occipital 33  6
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2018; 44: 377–390
Cortical neuronal loss in multiple sclerosis 385
with the cortical volume in both MS brain and control
tissue (Figure 3E–G). There are, of course, some caveats
in comparing results derived from histology of pro-
cessed post mortem tissue with data acquired using MRI
in pwMS in vivo. The process of fixation leads to
changes of MRI indices, such as relaxation times and
diffusion [40,41]; some degree of shrinkage may have
taken place as a result of tissue fixation [42], over and
above the volume reduction due to the dehydrating
process of tissue embedding, which in our sample was
25–28%.
In spite of the above-mentioned limitations, we there-
fore infer from the association between the number of
cortical neurons and the cortical volume detected in
our study that indices of cortical volume acquired
using MRI may provide a reasonable estimate of the
number of neocortical neurons during life. The weak
association between WM volume and the number of
neocortical neurons in pwMS underpins in vivo MRI
studies indicating WM volume is a far less robust pre-
dictor of cortical pathology [43,44].
While the difference in total cortical volume between
MS and controls did not reach statistical significance,
the magnitude of this difference – 26% smaller volume
in MS brain – would be consistent with an annual cor-
tical atrophy of just under 1%, which is similar to fig-
ures obtained using MRI in pwMS in vivo [44].
Several MRI studies reported regional variation of
cortical volume reduction in pwMS [45,46]. However,
we did not detect such variation with the degree of cor-
tical volume loss being very similar across all regions.
One explanation for this difference would be that local
volume variation may present at early disease stages
and becomes less apparent in chronic MS [47,48].
Significant neocortical demyelination was detected in
our samples. The degree of demyelination varied, simi-
lar to previous observations [11], between 46% (frontal
cortex) and 33% (occipital cortex), which is in contrast
to our cortical volume measures that suggested a virtu-
ally identical degree of atrophy across all lobes. While
earlier pathology studies suggested a mild effect (10%)
of cortical demyelination on neocortical neuronal loss
[13,21,22], our study did not reveal any association
whatsoever between the extent of demyelination and
the density of neurons in the MS neocortex. This find-
ing corroborates recent research on a smaller number
of tissue samples which indicated neuronal loss in the
MS neocortex compared to controls, however, showing
no difference in the number of neurons between
lesional and nonlesional MS neocortex [23].
The observed lack of association between the volume
of WM and both the neocortical myelination and neu-
ronal loss in each slab, suggests that, at least in
advanced stages of MS, these two key pathological fea-
tures may become partially independent. Assuming an
association between demyelination and neuroaxonal
loss does exist in early MS, well described for acute
lesions in the WM [49,50], the detected lack of such
relationship in the GM in late stage MS remains poorly
understood. Numerous hypotheses are being explored
including the contribution of anterograde (Wallerian)
and retrograde (‘dying back’) axonal degeneration [51]
due to remote lesions located some distance away
[52,53], meningeal inflammation [11] not necessarily
targeting myelin proteins [54], chronic microglia acti-
vation [55], gliosis [56], oxidative stress and mitochon-
drial dysfunction [57], primary neurodegenerative
processes [58] and exhaustion of CNS repair mecha-
nisms [59], all of which may contribute to worsening
disease in pwMS without overt inflammatory demyeli-
nation [12].
While lesions detected using conventional T2-
weighted MRI in patients with long-standing MS are
not specific for the underlying tissue condition (de-/
remyelination, axonal damage, gliosis, inflammation,
etc.), the majority of those lesions will be of the chronic
inactive type with significant axonal loss and sparse
remyelination [60]. And while chronic disease deterio-
ration is rather uniform and relentless [61], association
with lesions on T2-weighted MRI as a proxy of inflam-
matory demyelination is no longer robust at this stage,
in line with the relative independence of disability
accrual (considered driven by neuroaxonal loss) from
relapses (considered the clinical manifestation of
inflammatory demyelination) [62]. These findings are
also corroborated by the poor response of people with
worsening MS to purely systemic immunomodulatory
and immunosuppressive therapy [63]. The poor pre-
diction of disability based on lesions detected on
T2-weighted MRI is one of the key reasons why mea-
sures of brain volume have become such important
indices to predict clinical outcome.
The lack of correlation in chronic MS between neo-
cortical demyelination and neuronal loss is also strik-
ingly similar to the lack of such association between
the total amount of demyelination and axonal loss in
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the chronic MS spinal cord [64]. It will be of interest to
investigate these relationships using post mortem tissue
of the entire neuraxis, which to our knowledge has
only been performed once in a relatively limited sample
[65].
Limitations of the study
While the observed cortical atrophy could be caused
entirely by the loss of neurons, its cellular basis should
be addressed in further stereology studies also assess-
ing: neuronal size, dendritic and synaptic pathology
and the loss of other neocortical cell populations, such
as microglia and oligodendrocytes.
In particular, dysfunction and loss of synapses, a
pathological finding common to a number of chronic
neurological diseases [66], has recently received atten-
tion also in the context of MS and its animal model
experimental autoimmune encephalitis [67]. In pwMS,
synaptic loss has been reported in the hippocampus
associated with demyelination [68] and the presence of
the complement system proteins C1q and C3 [69]. Sub-
sequent studies reported synaptic damage and loss in
the cortical GM [22,70,71] and the cerebellar dentate
nucleus [72]. It is possible that synaptic loss could con-
tribute as an additional factor to cortical atrophy
together with the observed neuronal loss. Further stud-
ies are therefore warranted to investigate the interrela-
tionship between synaptic loss, demyelination and
volume change in pwMS.
In spite of these limitations, the strength of the
detected association between cortical volume and num-
ber of neurons in our data, corroborated by recent evi-
dence from a MRI/pathology study [27], supports the
use of MRI indices of brain – particularly cortical –
atrophy as a predictor of neuronal loss.
In conclusion, we provide robust evidence that in
chronic MS (i) neocortical neuronal loss is ultimately
decreased by nearly 40%, (ii) the impact of demyelina-
tion on neuronal density as well as cortical volume
appears limited and (iii) cortical volume is a strong pre-
dictor of number of cortical neurons. By inference, we
hypothesize MRI indices of cortical and brain atrophy
can provide a useful tool to predict an important
degenerative component of MS. Further validation of
this hypothesis through correlative MRI/pathology
studies is warranted.
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Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1. Findings suggestive of additional neurode-
generative pathology. Positive tissue controls for
a-synuclein (A), ab-amyloid (B) and Tau (C). Images
acquired with a 409 objective, scale bar = 30 lm. No
Lewy bodies and/or synuclein-positive intracytoplas-
matic inclusions were observed in any of the brains
examined: controls (D) and multiple sclerosis (MS) (G),
images acquired with 209 objective, scale bar
= 100 lm. Sparse ab-amyloid plaques were observed
in the neocortex, but not the hippocampus, of one con-
trol (E, image acquired with a 209 objective, scale
bar = 100 lm) and one people with MS (H, image
acquired with 109 objective, scale bar = 100 lm).
Very sparse Tau-positive neurons were observed in the
dentate gyrus and the neocortex of one healthy control
(F) and two MS cases (I), images acquired with a 209
objective, scale bar = 100 lm.
Table S1. All antibodies and antigen retrieval details.
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